Answers are grounded in this paper and cite their sources.
Two of 6 patients (33.3%) with SCCOHT achieved durable CR/iCR and long-term survival with ipilimumab plus nivolumab. Correlative studies to determine response and resistance markers are ongoing.
No takes yet. Share an insight, caveat, or question.
Chae et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: